92 results about "Pharmaceutics" patented technology

The invention relates to a flavonoid active fraction of an Abelmoschi corolla, a preparation method and an application thereof, and belongs to the field of traditional Chinese pharmaceutics. A high-purity Abelmoschi corolla flavonoid active fraction is prepared, which is found to have better therapeutic activity for kidney disease, and especially have a significant therapeutic effect for diabetic kidney disease and lupus nephritis, or contrast-induced kidney injury and eye diseases. Meanwhile, the Abelmoschi corolla flavonoid active fraction described in the invention also has good safety.

The present invention relates to the field of pharmaceutics, and discloses a water-in-water deep eutectic solvent microemulsion, which comprises: a hydrophobic deep eutectic solvent, which is prepared by mixing at least two components according to a specific ratio, and the two components are respectively a terpenoid solvent and a fatty acid solvent; an emulsifier; an aqueous phase comprising an emulsifier and water; wherein the microemulsion is an oil-in-water type microemulsion, and the average particle size of the microemulsion is less than 300nm; the hydrophobic deep-eutectic solvent is a solvent prepared by mixing a diterpenoid solvent and a fatty acid solvent according to a weight ratio of 1: 9 to 9: 1. By adopting the deep eutectic solvent technology, the hydrophobic deep eutectic solvent is used for replacing a traditional oil solvent, the solubility of the quercetin is effectively improved, and the highest drug loading capacity of the quercetin in the preferable hydrophobic deep eutectic solvent can reach 23 mg / mL and is improved by 2000-3000 times compared with the highest drug loading capacity of the quercetin in water which is only 1 microgram / mL.

The present invention relates to a pharmaceutical dosage form comprising lanosterol and a derivative thereof, and cyclodextrin, the pharmaceutical dosage form according to one embodiment having an effect of improving water solubility and in vivo absorbability, thereby increasing bioavailability.

The invention provides compositions comprising a single protein having one or more molecules of a pharmaceutical agent tightly bound therein. The compositions are useful to decrease the toxicity and / or to widen the therapeutic window of the pharmaceutical agent. The invention also provides methods for preparing such a composition.

The present invention relates to the field of medical technology, and specifically to the use of salvianolic acid B in the preparation of drugs for treating IPEX. The present invention proves through in vivo animal experiments that salvianolic acid B has a good anti-inflammatory effect and can effectively alleviate the autoimmune reaction of Treg-deficient SF mice. In the present invention, the cations in the salvianolic acid B salts can be iron ions, calcium ions, sodium ions, potassium ions or magnesium ions, preferably magnesium ions; the dosage form of the drug for treating IPEX can be any dosage form described in pharmacy, and can be an oral liquid form, an injection form, a tablet form or a capsule form. By utilizing the key role of salvianolic acid B in IPEX disease, it can be prepared into a drug, providing a theoretical basis and a new treatment idea for the treatment of primary immunodeficiency diseases with traditional Chinese medicine; salvianolic acid B is easy to obtain, can be quickly put into production and obtain a high-efficiency preparation, and has important application value.

The invention discloses a double-drug-loading cationic mixed micelle as well as a preparation method and application thereof, and belongs to the field of pharmaceutics. The micelle is composed of a cationic polymer PEI-stearamide (PSA), an amphiphilic polymer DSPE-PEG2000, a hydrophobic drug resveratrol (RES) and a hydrophilic drug catalase (CAT). The preparation method comprises the following steps: 1) synthesizing PSA; the preparation method comprises 1, dissolving RES, PSA and DSPE-PEG2000 in an organic phase, injecting the obtained solution into a water phase, and carrying out rotary evaporation to obtain RES-loaded micelle (RES / PSA-PEG), and 3, adding a CAT solution to the micelle solution in a dropwise manner to obtain co-loaded micelle (RES / PSA-PEG / CAT). The micelle can effectively penetrate a corneal barrier and target a retinal pigment epithelial layer and a choroidal membrane.Through eye drop administration, RES anti-oxidation and anti-inflammatory effects and CAT hydrogen peroxide removal effects can be synergistically exerted, and an AMD curative effect can be substantially enhanced.

The present invention belongs to the technical field of pain relief preparations, and particularly relates to a pain relief preparation, a preparation method thereof and an application. The pain relief preparation is composed of (+)-camphene, a propylene glycol extract of Bupleurum chinense DC. and pharmaceutically acceptable excipients. Among them, the mass ratio of (+)-camphene to the propylene glycol extract of Bupleurum chinense DC. is 1-2.5:1. The propylene glycol extract of Bupleurum chinense DC. is prepared by the following method: Bupleurum chinense DC. is ground into powder, mixed with propylene glycol, extracted by ultrasonic treatment, filtered, the filtrate is collected and dried to obtain the propylene glycol extract of Bupleurum chinense DC. The present invention also provides a preparation method of the pain relief preparation, and proves the application of the pain relief preparation in relieving acute pain and postherpetic neuralgia, expanding the types of pain relief preparations.

The invention discloses a chondroitin sulfate modified dihydromyricetin solid lipid nanoparticle, and belongs to the field of pharmaceutics. The nanoparticle is composed of a solid lipid component, dihydromyricetin encapsulated in the solid lipid component and a chondroitin sulfate targeting ligand modified on the surface. According to the invention, the chondroitin sulfate is specifically combined with the high-expression CD44 receptor on the surface of the hepatic stellate cell, so that the active targeting delivery of the drug to the hepatic fibrosis focus is realized. The nanoparticles have the characteristics of uniform particle size, high encapsulation efficiency and good slow release effect, can significantly improve the enrichment concentration of dihydromyricetin in the liver, enhance the anti-hepatic fibrosis curative effect and reduce the systemic side effects, and have good application prospects in preparation of hepatic fibrosis targeted therapy drugs.

The present invention relates to the technical field of pharmaceutics, and in particular to a triptolide lignocerate, a liposome thereof and a preparation method therefor. The chemical structural formula of the triptolide lignocerate is represented by formula (I). The triptolide lignocerate provided by the present invention is obtained by esterification of triptolide C14-OH and lignoceric acid. The anti-tumor effectiveness, safety and the like of the triptolide lignocerate liposome are further improved with respect to the prior art, so that a foundation is laid for providing safer and more effective triptolide-related clinical preparations.

The invention relates to a pharmaceutical composition for treating or improving intestinal leakage and / or blood-brain barrier injury induced by sleep deprivation and application of the pharmaceutical composition, and belongs to the field of medicines.The pharmaceutical composition is prepared from 5-60 parts of honey-fried licorice roots, 5-35 parts of dried ginger, 5-35 parts of radix paeoniae alba, 5-35 parts of cinnamon, 5-35 parts of pseudo-ginseng and 2-12 parts of leeches. The pharmaceutical composition disclosed by the invention can be processed into pharmaceutically acceptable oral dosage forms such as granules, powder and the like; the pharmaceutical composition provided by the invention can improve expression of tight junction protein of vascular endothelial cells and intestinal epithelial cells, reduce the level of blood-brain barrier and intestinal barrier injury markers in blood, improve expression of tight junction protein in blood-brain barrier and intestinal barrier of sleep deprivation patients, reduce influence caused by sleep insufficiency and improve sleep deprivation effect. A new thought is provided for treating the injury problem caused by sleep insufficiency in traditional Chinese medicine.

The present application relates to the technical field of pesticides, in particular to a kind of pyraclostrobin and prochloraz microemulsion and its preparation method and application, by weight percentage, including: pyraclostrobin 5-20%, prochloraz 20-40%, emulsifier 10%-34%, fertilizer compatible agent 6%-10%, solvent 5%-12%, cosolvent 8-15%, deionized water is made up to 100%.By adopting pyraclostrobin and prochloraz as effective active ingredients, under the action of specific emulsifier, fertilizer compatible agent, solvent and cosolvent, a microemulsion product with good pharmaceutical properties is obtained, which can cope with high and low temperature environment, adapt to various regional environments, transportation conditions and storage conditions, and the raw material is environmentally friendly, effectively reducing soil pollution, and has important significance for application in industry.

This invention discloses the application of the Miao medicine Liao's Huafengdan in the preparation of drugs for the prevention and treatment of multiple myeloma, belonging to the field of pharmaceutical application technology. In vitro detection using RPMI8226 and MM1.S multiple myeloma cells revealed that Liao's Huafengdan has a significant inhibitory effect on multiple myeloma. Flow cytometry analysis further showed its effect on cell apoptosis, indicating that Liao's Huafengdan significantly affects apoptosis in multiple myeloma cells, with higher drug concentrations leading to more pronounced apoptosis. Therefore, it can be used as a preparation for the prevention and treatment of multiple myeloma, and can be formulated into pharmaceutically permissible oral liquids, injections, tablets, capsules, and drop pills, providing a new application for Liao's Huafengdan. Moreover, Liao's Huafengdan is already a marketed drug and can be directly applied to humans without further clinical safety assessments, which can rapidly increase the market share of this product.

The invention relates to pharmaceutics, and more particularly to gastroenterology, and can be used for the prophylaxis or treatment of inflammatory diseases of the gastrointestinal tract. What is described is the use of trimebutine maleate to achieve a maximum change in the level of the proinflammatory cytokines IL-1, IL-6, TNF-α, NF-κB and the anti-inflammatory cytokine IL-10 in the gastrointestinal tract for the prophylaxis or treatment of acute and chronic inflammatory diseases of the gastrointestinal tract.

The invention discloses licochalcone A flexible liposome and a preparation method thereof, and belongs to the field of pharmaceutics. The liposome is prepared from licochalcone A; soybean phospholipids; the invention relates to a skin care product, which is characterized by consisting of cholesterol and a membrane softener, wherein the membrane softener comprises isopropyl myristate (IPM) and polyoxyethylated castor oil (PCO). By adding IPM and PCO, the physical characteristics and transdermal performance of the liposome are improved, so that the medicine can penetrate through the skin and enter tissues, and the anti-inflammatory activity is better exerted. The liposome also has the excellent characteristics of small particle size, uniform distribution, high encapsulation efficiency, long storage period and the like, and has a good application prospect in the development of skin anti-inflammatory external medicines.

The invention discloses an ebastine tablet and a preparation method thereof. The ebastine tablet is prepared from the following raw material components in parts by weight: 7 to 10 parts of ebastine, 13 to 22 parts of microcrystalline cellulose, 66 to 90 parts of lactose, 3 to 6.5 parts of pregelatinized starch, 4 to 6.5 parts of croscarmellose sodium and 1.0 to 2.6 parts of magnesium stearate. A wet granulation process is adopted, granules prepared by the process are good in flowability and compressibility, qualified in quality and stable in property, and the medicine is a pH dependent medicine and cannot reach tank leakage conditions in media with the pH of 4.5, water and pH of 6.8. In combination with biological pharmacy and pharmacokinetic data of drugs, ebastine is a BCS2 compound, the ebastine can reach a peak in vivo quickly, the peak time is about 2 hours, and the peak time of a main metabolite carristine of the ebastine in vivo is 4.5-6 hours.

The application belongs to the technical field of medicines, and relates to an N-H aporphine nitrogen-containing heterocyclic derivative, a preparation method and application thereof.The N-H aporphine nitrogen-containing heterocyclic derivative comprises a compound shown in a general formula M, isomers thereof and pharmaceutically acceptable salts or hydrates thereof.The application introduces a nitrogen-containing heterocyclic ring into an aporphine derivative, and the disclosed N-H aporphine nitrogen-containing heterocyclic derivative can be applied in the preparation of medicines for preventing and / or treating obesity, urinary incontinence, depression, anxiety, obsessive-compulsive disorder, epilepsy, schizophrenia, pain, diabetes and drug addiction.

The invention belongs to the field of pharmaceutics, and particularly relates to a composition containing budesonide and formoterol, and the composition provided by the invention is in a specific pH range, adopts a specific surfactant addition mode, also adopts moist heat sterilization, and is free of toxic and side effects. The prepared inhalation suspension of formoterol and budesonide has better delivery rate and total delivery amount, better fine particle fraction and smaller particle size distribution, has the advantages of low temperature, short time, strong penetrating power, economy, rapidness and the like compared with dry heat sterilization and moist heat sterilization, and is more suitable for industrial mass production.

The present invention relates to a use of a compound represented by formula (I) and a pharmaceutically acceptable salt thereof in the field of pharmaceutics, and in particular an application thereof in the preparation of a drug for treating pneumonia.

The invention belongs to the field of pharmaceutics, particularly relates to a composition containing levosalbutamol hydrochloride and ipratropium bromide as well as a preparation method and application of the composition, and overcomes the defects of a stabilizer disodium ethylene diamine tetraacetate adopted in the prior art. The invention provides a levosalbutamol hydrochloride and ipratropium bromide composition which is simpler in prescription and better in safety, can be used for treating reversible bronchospasm related to airway obstructive diseases, can jointly act on muscarinic acid and beta2 adrenergic receptors in the lung, can enhance the bronchiectasia effect, takes effect quickly, and is free of toxic and side effects. The clinical application value is very high.

The invention relates to pharmaceutics, and more particularly to gastroenterology, and can be used for the prophylaxis or treatment of inflammatory diseases of the gastrointestinal tract. What is described is a pharmaceutical composition having antibiotic activity, characterized in that it contains a therapeutically effective amount of crystalline rifaximin in anhydrous form.

The invention relates to the technical field of pharmaceutics, in particular to a monoclonal antibody preparation for inhibiting fibrosis after an eye operation and application. The anti-periostin humanized monoclonal antibody injection preparation provided by the invention is prepared from the following components: an anti-periostin humanized monoclonal antibody, a buffering agent, amino acid, polysorbate and trehalose. The preparation is stable in property. The biological activity is good, and the stimulation to eyeballs can be reduced.

The invention discloses a sodium hyaluronate composition and application of the sodium hyaluronate composition in preparation of medicines for preventing and treating knee osteoarthritis, and belongs to the field of medicines. The composition is an oral preparation, and the oral preparation is prepared from sodium hyaluronate, cortex acanthopanacis, caulis polygoni multiflori, radix achyranthis bidentatae, pawpaw, radix astragali and pharmaceutically acceptable auxiliary materials. Sodium hyaluronate is combined with'arthralgia-removing powder 'to treat knee osteoarthritis, and results of clinical tests show that by combining the two medicines, knee joint pain can be effectively relieved for a long time, knee joint activity can be improved, swelling can be eliminated, comprehensive functions of knee joints can be improved, patients do not relapse after drug withdrawal, and existing treatment effects can still be maintained.

The group of inventions relates to chemistry, medicine and pharmaceutics, and more particularly to a liquid aerosol composition for the protection of wounds and to a wound protection method. The proposed liquid aerosol composition comprises a film-forming solution of a polymer in an organic solvent, and a propellant, wherein the film-forming solution consists of 2-5 wt.% styrene-ethylene-butylene-styrene (SEBS) block copolymer and 95-98 wt.% organic solvent selected from among dichloromethane, cyclohexane or a mixture thereof, and the propellant is a hydrocarbon propellant or dimethyl ether. According to the proposed method, the liquid aerosol composition is applied to the surface of a wound from a distance of 10-20 cm for 10-15 seconds by spraying from an aerosol can, wherein a polymer film is formed within 30-60 seconds and the formed polymer film has a thickness of 0.006-0.010 mm. The group of inventions provides an elastic film which has good adhesive properties and an optimal moisture vapour transmission rate.

The present invention relates to a salt and crystal form of an AT2R agonist and use thereof in pharmaceutics, and specifically relates to a salt and crystal form of methyl ((4-fluoro-5-isobutyl-3-(4-((2-(trifluoromethyl)-1H-imidazol-1-yl)methyl)phenyl)thiophen-2-yl)sulfonyl)carbamate (a compound represented by formula (I)) and use thereof in pharmaceutics.

The invention discloses a drug controlled release system based on optimal drug delivery sequence optimization and a preparation method and application thereof, and belongs to the field of pharmaceutics. The preparation method comprises the following steps: preparing a docetaxel nano preparation, and preparing poloxamer F-127 gel by adopting a cold dissolving method; metformin is dissolved in PBS to prepare a metformin solution, poloxamer F-127 gel, the metformin solution and an aqueous solution of a docetaxel nano preparation are stirred and dispersed uniformly in proportion to a homogeneous sol state, and the drug controlled release system optimized based on the optimal drug delivery sequence is obtained. According to the innovatively designed drug controlled release system MD (at) Gel, based on drug molecular weight and hydrophilic and hydrophobic differences, the metformin released firstly can block tumor cells in a mitosis G2 / M region, and the anti-tumor effect of docetaxel is remarkably improved by improving the immunosuppression microenvironment of tumors. The invention provides an innovative administration strategy and implantable instrument support for sequential chemotherapy of solid tumors.

The invention provides compositions comprising a single protein having one or more molecules of a pharmaceutical agent tightly bound therein. The compositions are useful to decrease the toxicity and / or to widen the therapeutic window of the pharmaceutical agent. The invention also provides methods for preparing such a composition.

The application discloses a nano-suspension preparation of juglone, which is mainly prepared from 5-15 parts of juglone and 1-20 parts of a stabilizer by weight. The application also adopts a reverse solvent method-high pressure homogenization method to establish a corresponding preparation method, which is simple in process and can obtain smaller drug particle size, thereby improving the drug bioavailability and enhancing the anti-tumor effect. Therefore, the application prepares a novel traditional Chinese medicine nano-preparation of juglone through the means of pharmacy, effectively improves the solubility and bioavailability of juglone. The in-vitro anti-tumor activity experimental results show that the nano-suspension preparation has significant inhibitory activity on the growth of various tumor cells, can be used for preparing drugs for preventing and treating related tumors, increases the targeting and bioavailability of the drug on tumors, reduces the toxicity, provides a new method and strategy for clinical treatment, and has good market prospect and high social value and economic value.

The inventions relate to medicine and pharmaceutics and can be used in the treatment of iron-deficiency anemia. A method for producing a composition of water-soluble readily absorbable bivalent iron includes dissolving an organic reducing compound in water and adding a source of iron(II), wherein the molar ratio of the organic reducing compound to the iron(II) source is from approximately 3:1 to 10:1. A composition of water-soluble readily absorbable bivalent iron is produced using the claimed method, and a hermetically sealed ampoule is used in a method for delivering said composition. The result is the fast and effective treatment of iron-deficiency anemia in patients.

The invention discloses a permeation-promoting and solubilizing meloxicam transdermal patch, and belongs to the field of pharmaceutics. The patch consists of a backing layer, a drug-loading pressure-sensitive adhesive layer and an anti-sticking layer, wherein the drug-loading pressure-sensitive adhesive layer consists of a solvent type pressure-sensitive adhesive, meloxicam, a penetration enhancer and a solubilizer. According to the patch, transdermal delivery of meloxicam is achieved, various penetration enhancers and solubilizers are systematically screened, so that meloxicam in the patch is continuously administered at a proper transdermal permeation rate, effective blood concentration can be maintained in a relatively prolonged time, the administration frequency is reduced, and the problem that the in-vitro accumulated permeation amount of the meloxicam patch is low is solved. The meloxicam patch has the characteristics of high percutaneous penetration amount and continuous administration, and is effectively used for skin administration treatment of osteoarthritis and rheumatoid arthritis.

This invention relates to a pharmaceutical formulation and more particularly to one for Active Pharmaceutical Ingredients (APIs) which are recognised under the Biopharmaceutical Classification System (BCS) as a Class I, III or III drug. In addition to the API, it comprises a combination of gelling agents comprising: a primary gelling agent which is agar and a secondary gelling agent which is an alginate together with at least one cation donator, a preservative, and water and optionally a thickening agent, sweetener(s) and flavouring.